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A B S T R A C T
Dientamoeba fragilis is a trichomonad parasite of the human intestine that is found worldwide. However, the
biological cycle and transmission of this parasite have yet to be elucidated. Although its pathogenic capacity has
been questioned, there is increasing evidence that clinical manifestations vary greatly. Different therapeutic
options with antiparasitic drugs are currently available; however, very few studies have compared the effec-
tiveness of these drugs. In the present longitudinal study, we evaluate 13,983 copro-parasitological studies using
light microscopy of stools, during 2013–2015, in Terrassa, Barcelona (Spain). A total of 1150 (8.2%) presented
D. fragilis. Of these, 739 episodes were finally analyzed: those that involved a follow-up parasitology test up to 3
months later, corresponding to 586 patients with gastrointestinal symptoms (53% under 15 years of age).
Coinfection by Blastocystis hominis was present in 33.6% of the subjects. Our aim was to compare therapeutic
responses to different antiparasitic drugs and the factors associated with the persistence of D. fragilis post-
treatment. Gender, age, and other intestinal parasitic coinfections were not associated with parasite persistence
following treatment. Metronidazole was the therapeutic option in most cases, followed by paromomycin: 65.4%
and 17.5% respectively. Paromomycin was found to be more effective at eradicating parasitic infection than
metronidazole (81.8% vs. 65.4%; p= 0.007), except in children under six years of age (p= 0.538). Although
Dientamoeba fragilismainly produces mild clinical manifestations, the high burden of infection means we require
better understanding of its epidemiological cycle and pathogenicity, as well as adequate therapeutic guidelines
in order to adapt medical care and policies to respond to this health problem.
1. Introduction
Dientamoeba fragilis is a non-flagellated trichomonad protozoan
parasite which inhabits the human intestine and is found worldwide
(Barratt et al., 2011). The prevalence of D. fragilis is very hetero-
geneous, depending on the geographical region and the diagnostic
method used (Barratt et al., 2011; van Gestel et al., 2018), with highest
levels of prevalence observed in high-income countries (Stark et al.,
2016). In Europe, prevalence varies from 1.6% to 83% (González-
Moreno et al., 2011; Preiss et al., 1990); in Spain, from 0.4% to 24% in
children (Belda Rustarazo et al., 2008) and from 2% to 9% in adults
(González-Moreno et al., 2011; Fernández-Suarez et al., 2015).
The transmission and biological cycle of D. fragilis have not been
reported, although fecal–oral transmission is most probable
(Munasinghe et al., 2013; Stark et al., 2016). In recent years, a cystic
form of infection has been reported, which may explain how D. fragilis
remains in the environment and could be a vehicle that mediates
transmission between hosts (Stark et al., 2014).
In relation to the pathogenic capacity of D. fragilis, animal studies
have reported the proposals of Kock (Munasinghe et al., 2013); while in
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humans an association has been detected between gastrointestinal
symptoms, the presence of the parasite and improvements in clinical
manifestations post-treatment (Stark et al., 2005; Banik et al., 2011;
Barratt et al., 2011; Nagata et al., 2012). Meanwhile, some authors have
not found clinical improvement after eradication of the parasite in feces
(Johnson et al., 2004; Röser et al., 2014; Wong et al., 2018).
Clinical presentations vary from the absence of symptoms to gas-
trointestinal symptomatology mainly of abdominal pain and diarrhea
(Miguel et al., 2018; Damien Stark et al., 2010). Some studies have
related the clinical presentation of D. fragilis with the irritable bowel
syndrome (Yakoob et al., 2010) and with eosinophilic colitis (Cuffari
et al., 1998).
The principal diagnostic techniques used for the diagnosis of D.
fragilis are light microscopy and polymerase chain reaction (PCR) am-
plification of DNA from stools together with subsequent sequencing.
PCR has been reported to have the higher sensitivity of these two
methods (van Gestel et al., 2018). However, the correlation between
PCR and clinical signs and symptoms seems to be lower than for light
microscopy (Stark et al., 2010a,b).
Many therapeutic options for the treatment of infection by D. fragilis
have been adopted in symptomatic cases. The main groups of anti-
parasitic drugs include: the nitroimidazoles, among which me-
tronidazole and also secnidazole, tinidazole and ornidazole are of note
(Banik et al., 2011; Girginkardeşler et al., 2003; Kurt et al., 2008; Röser
et al., 2014; Stark et al., 2014); aminoglycosides, with paromomycin
(Vandenberg et al., 2007; van Hellemond et al., 2012); hydro-
xyquinolines, such as iodoquinol and clioquinol (Spencer, 1979; Millet
et al., 1983; Stark et al., 2010a,b; Schure et al., 2013) and tetracyclines
(Preiss et al., 1990). In vitro studies of antiparasitic drugs do not seem to
correspond with clinical responses observed in humans (Chan et al.,
1994; Nagata et al., 2012).
Eradication rates in studies of treatment effectiveness vary greatly.
In addition, the percentage of spontaneous cures without treatment are
elevated (almost 50%) (Stark et al., 2016). At a European level, era-
dication rates among children range from 49% to 100%, and from 57%
to 98% in adults (van Gestel et al., 2018). Most studies of D. fragilis
treatment are retrospective and have a small sample sizes (Nagata et al.,
2012; Röser et al., 2014; van Gestel et al., 2018). Due to the scarcity of
randomized comparative studies, there is little evidence indicating
which adult or pediatric cases of D. fragilis should be treated, or what
the treatment of choice and best therapeutic schedule are (Stark et al.,
2016).
The aim of the present study was therefore to evaluate therapeutic
responses to different antiparasitic drugs and to determine the factors
which may be associated with persistence of D. fragilis infection.
2. Material and methods
2.1. Study population
We performed a longitudinal study from 2013 to 2015 in the areas
of the western Vallès Occidental and the Baix Llobregat, in the province
of Barcelona, Spain. The study population included individuals who
attended any of the nine primary health care centers or the Mutua de
Terrassa hospital, and who underwent a parasitological stool study in
response to gastrointestinal symptomatology. Of these individuals,
those with a positive test for D. fragilis were selected for the study. Data
were obtained from the results of the corresponding laboratories.
2.2. Data
Three stool samples per patient were collected on alternate days, in
stool containers with sodium acetate–acetic acid–formaldehyde (SAF).
They were processed by the centrifugal sedimentation technique and
examined under a light microscope (Martín-Rabadán et al., 2010). We
defined an episode as an infection by D. fragilis when an individual
presented D. fragilis in at least one of the three samples. The study in-
cluded episodes that were not treated with antiparasitic drugs as well as
those that were followed by a parasitology test at some point up to three
months after diagnosis. Persistence of D. fragilis infection was defined
when the follow-up parasitology test was still positive for D. fragilis.
Sociodemographic data (age and gender) of the patients were col-
lected from the electronic clinical history as well as their diagnostic
data (parasitology results in stool samples, coinfections with other
parasites, time to follow-up parasitology test) and the treatment ad-
ministered (antiparasitic drug). In agreement with the 2017 treatment
guidelines issued by the Center for Disease Control and Prevention
(CDC-Centers for Disease Control, 2017), metronidazole (500–750mg)
was administered orally three times daily to adults and 30mg/kg/day
to children for 10 days; while oral paromomycin (25–35mg/kg/day)
was divided into three doses for 7 days in adults and children. Ther-
apeutic failure or persistence was considered when D. fragilis was de-
tected in the post-treatment test, while a negative test indicated era-
dication.
2.3. Statistical analysis
Qualitative variables were described using frequencies and per-
centages; quantitative variables using medians, means, and the inter-
quartile range (IQR).
The chi-square or Fisher's exact test was used to assess the asso-
ciation between categorical variables and persistence; in the case of
quantitative variables, the Mann-Whitney U test was used. In addition,
the generalized estimation equation was used to determine the in-
dependent factors associated with persistence, and an exchangeable
correlation structure was assumed for repeated episodes in a subject.
The variance-covariance matrix of the regression parameter coefficients
was estimated by a robust sandwich variance estimator. The type I error
was set at 5%. The analysis was performed using IBM SPSS Statistics 25
(SPSS Inc., Chicago, IL, USA).
2.4. Ethics
The study was approved by the Ethical Research Committee of the




A total of 13,983 three-stool-sample tests were studied from the
three-year period. D. fragilis was identified in 1150 episodes of infection
(8.2%), and of these, 739 (64.3%) underwent a post-treatment para-
sitology test within the following three months and were included in
the analysis. These 739 episodes of infection corresponded to 586 pa-
tients, 152 (25.9%) of whom presented more than one episode during
the study period.
Women made up 52.6% (308/586) of the individuals studied, and
the mean age of the study subjects was 12 (IQR: 6–46). Concerning
coinfection with other intestinal parasites, Blastocystis hominis was ob-
served in 33.6% (248/739) followed by Giardia lamblia in 4.2% (31/
739). Metronidazole was administered in 65.4% (483/739) of the epi-
sodes of infection, while paromomycin was given in 17.5% (129/739),
and 8.9% (66/739) received no treatment (Table 1).
Some individuals presented several episodes of infection by D. fra-
gilis during the study period: 21.2% of women and 16.9% of men, with
no significant differences (p= 0.181). By age groups, the percentages
were: 15.9% in individuals below 6 years of age, 21.9% in those aged
from 6 to 14, and 18.9% in individuals aged 15 or over (p=0.399).
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3.2. Analysis of factors associated with the persistence of D. fragilis
D. fragilis persisted in 33.8% (250/739) of the episodes. Neither
gender (p= 0.419) nor patient age (p=0.107) was associated with
persistence, and there was no statistical association between persistence
and parasitic coinfection. However, we did observe that the longer the
time between the first diagnosis and the post-treatment parasitology
test, the greater the proportion of positive cases for D. fragilis: 27.4% in
the first month, 34.2% in the second month and 40.4% in the third
month (p=0.012) (Table 2).
Our multivariate analysis to evaluate the possible factors associated
with the eradication of D. fragilis included age, gender, treatment, co-
infection with Blastocystis hominis and time from diagnosis to the
follow-up parasitology test. Eradication was only associated with anti-
parasitic treatment in comparison with non-treated subjects, showing a
greater probability of eradication with paromomycin (OR=5.64,
95%CI: 2.51, 12.6), followed by metronidazole, (OR=1.84, 95%CI:
1.10, 3.08), and other treatments (OR=1.74, 95%CI: 0.90, 3.35)
(Table 3).
3.3. Study of antiparasitic drugs
With regard to the therapy used, we observed that eradication was
achieved in 65.4% of patients treated with metronidazole and 81.8% of
those treated with paromomycin, both higher than for non-treated pa-
tients (48.5%) (p=0.007 and p < 0.001, respectively). These eradi-
cation rates did not change when combined treatments were adminis-
tered, as observed with the combination metronidazole plus
mebendazole compared to metronidazole (70.8% versus 65.4%
p=0.378) or with paromomycin plus mebendazole compared to par-
omomycin (87.5% versus 81.8%, p=0.580) (Table 4). Overall, par-
omomycin cured patients in 16.6% (95%CI: 7.9%, 25.1%; p < 0.001)
more cases than metronidazole did. On analyzing the treatments by age
group, this difference was not observed in individuals aged under six
(Table 5).
When we reviewed the metronidazole treatment regimen used in
each individual, we observed that in those who received the re-
commended dose and duration of treatment the eradication rate in-
creased to 73%. Nonetheless, paromomycin continued to present a
higher percentage of cure (p=0.013). With metronidazole schedules of
less than 10 days, the eradication rate was 64.5% (p=0.199), con-
sidering only doses less than 500 mg/8 h, it was 71.8% (p=0.97), and
if both the dose and treatment duration were less than those re-
commended, the rate of eradication rate was 45.6% (p < 0.001)
(Table 6).
Table 1
Characteristics of the patients and D. fragilis episodes, coinfection and
treatment.
n (%)
Individuals characteristics (n= 586)
Gender: Female 308 (52.6%)
Age (year) 12 (IQR:6; 46)
Episodes > 1 152 (25.9%)
Coinfection (episodes n= 739)
Blastocystis hominis 248 (33,6%)
Giardia Lamblia 31 (4.2%)
Enterobius vermicularis 4 (0.5%)





Persistence (episodes n=739) 250 (33.8%)
IQR: interquartile range.
Table 2
Study variables related to persistence of D. fragilis.

























Factors associated with the eradication of D. fragilis.
P- value OR [95%CI]
Women 0.834 1.04 [0.72; 1.46]
Age (years)a
≤5 0.873 1.04 [0.65; 1.66]
6-14 0.230 0.79 [0.54; 1.16]
Treatmenta
Paromomiycin < 0.001 5.64 [2.51; 12.6]
Metronidazole 0.002 1.84 [1.10; 3.08]
Others 0.098 1.74 [0.90; 3.35]
Coinfection by Blastocystis hominis 0.155 1.30 [0.91; 1.86]
Time until post-treatment control test (days)a
0–30 0.091 1.61 [0.93; 2.78]
31–60 0.639 1.11 [0.72; 1.68]
a Basal category; Age: ≥15, Treatment: Non-treatment, Time until test:
61–90 days.
Table 4
Eradication rates of D. fragilis according to antiparasitic drug administered.
Treatment %
Metronidazole alone 300/459 (65.4%)
Metronidazole + Mebendazole 17/24 (70.8%)
Metronidazole (total) 317/483 (65.6%)
Paromomycin alone 99/121 (81.8%)
Paromomycin + Mebendazole 7/8 (87.5%)
Paromomycin (total) 106/129 (82.2%)
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4. Discussion
The results of the present study show an elevated rate of D. fragilis
infection in patients with gastrointestinal symptoms (approximately
8%) and a high rate of persistence of D. fragilis (33%) after having re-
ceived treatment. Concerning treatment, we found that a broad range of
antiparasitic drugs and schedules were used, with metronidazole and
paromomycin the most commonly administered. Treatment with par-
omomycin presented higher rates of eradication of D. fragilis than me-
tronidazole at all ages, except in subjects under six years of age.
International treatment guidelines (CDC-Centers for Disease
Control, 2017) recommend metronidazole and paromomycin as first-
line treatment together with iodoquinol (not marketed in our country).
To date, studies of the effectiveness of treatment of D. fragilis have been
small (most include fewer than 100 subjects), they tend to study a
heterogeneous population (studies in children, children and adults and
adults), and generally include retrospective case series (CDC-Centers for
Disease Control, 2017; van Gestel et al., 2018). The eradication rates
reported vary greatly, with elevated rates of therapeutic failure (up to
80%) (Nagata et al., 2012; Stark et al., 2014; van Gestel et al., 2018).
With regard to the antiparasitic drugs used, metronidazole has been
studied more frequently, with eradication rates ranging from 52% to
85% (Banik et al., 2011; Engsbro et al., 2012; Kurt et al., 2008; Röser
et al., 2014; Schure et al., 2013; Damien Stark et al., 2010; van
Hellemond et al., 2012). To the best of our knowledge, only one ran-
domized, double-blind clinical trial with a placebo has been carried out
in a pediatric population, and the results showed that metronidazole
was no more effective than the placebo (Röser et al., 2014). Another
randomized clinical study with a single dose of ornidazole showed this
drug to be more effective than metronidazole (Kurt et al., 2008).
In relation to paromomycin, eradication rates from 80% to 100%
have been reported (Simon et al., 1967; Vandenberg et al., 2006, 2007;
Stark et al., 2010a,b; van Hellemond et al., 2012) in retrospective case
series. Our setting involved patients presenting gastrointestinal symp-
toms in the absence of other causes and always attributable to D. fra-
gilis. The most frequent therapeutic option was metronidazole. The re-
sults of our study suggest a clear advantage of paromomycin in the
treatment of infection by D. fragilis, which is consistent with the results
of van Hellemond et al. (2012).
In the subgroup of children under six years of age, in the bivariate
analysis, we observed that paromomycin presented lower rates of era-
dication than in subjects aged over six and was no more effective than
metronidazole. These lower rates could be due to the different phar-
macokinetics and pharmacodynamics of paromomycin in small chil-
dren. Some studies have reported possible underdosing when calcu-
lating the dose according to weight in pediatric populations and suggest
that the dose be calculated based on body surface (Lack and Stuart-
Taylor, 1997; Añez et al., 2016).
The schedules of dose and length of treatment are very hetero-
geneous in studies of the effectiveness of metronidazole in the treat-
ment of D. fragilis (Banik et al., 2011; van Gestel et al., 2018). In the
study by Banik et al. (2011), when they analyzed therapeutic failure, it
was not associated with either the dose or treatment duration. In con-
trast, in our study, both the dose and treatment time were found to be
associated with greater therapeutic failure, which was only significant
when the two were combined. Thus, the dose showing the best results
in our study was that of metronidazole 500–750mg or 30mg/kg/day in
children orally three times daily for ten days, which is the schedule
recommended by international guidelines (CDC-Centers for Disease
Control, 2017).
Concerning coinfection with other parasites, we did not observe any
relationship between the presence of other parasites and a worse re-
sponse to treatment. In our case, neither was the addition of me-
bendazole to the treatment used associated with higher eradication
rates, in contrast to some previous studies (Boga et al., 2016). Coin-
fection by B. hominis was the most frequently observed (33.6%), sug-
gesting that it could have a similar epidemiology. Meanwhile, nu-
merous studies have linked Enterobius vermicularis with the transmission
of D. fragilis (Johnson et al., 2004; Girginkardeşler et al., 2008; Röser
et al., 2014; Ögren et al., 2015). In our study, infection by E. vermicu-
laris was low (0.5%), although no diagnostic test of choice was used for
its diagnosis (Graham technique). The small number of individuals
treated with mebendazole combined with paromomycin or me-
tronidazole does not allow us to draw conclusions about the effective-
ness of these treatment options.
The apparently high rate of eradication of the parasite without
treatment may be explained by intermittent excretion of trophozoites in
stools (Cartwright, 1999) a possible reduction in parasitic load not
detectable by light microscopy, spontaneous eradication of the parasite
(Röser et al., 2014) and/or a limitation of the diagnostic technique (D.
Stark et al., 2010).
We also observed that one-fourth of the patients presented more
than one infectious episode by D. fragilis and that the longer the time
until the next parasitology test, the higher the rate of persistence. This
fact is consistent with the results of the study by Röser et al. (2014).
This phenomenon may have 2 explanations: the first is that eradication
is not achieved, but instead there is a reduction, albeit not detectable by
light microscopy, in parasitic load, and the longer the delay in the test
the higher the probability of detecting the parasite; and the second is
the possibility of new reinfection. Röser et al. (2014) reported similar
results with the use of molecular biology (with high sensitivity for low
parasitic loads) suggesting that the mechanism of reinfection was pre-
dominant.
The present study had a longitudinal observational design, limiting
the generalizations that are valid from the results of the study of as-
sociation and not causality. Clinical trials are needed to compare dif-
ferent antiparasitic drugs with a placebo to determine the real effec-
tiveness of treatment and to determine the best therapeutic options to
be implemented. The use of microscopic techniques (and not molecular
biology) may have reduced the sensitivity, but we believe that this did
not affect the overall value of the results, and the prevalence of D.
fragilis found was in agreement with values described in other European
Table 5
Percentage of D. fragilis eradication based on treatment and age group.
Treatment Age group
≤5 years 6–14years ≥15 years
Metronidazole 65/86 (75.6%) 79/136 (58.1%) 154/232 (66.5%)
Paromomycin 28/39 (71.8%) 37/44 (84.1%)* 36/40 (90.0%)**
Others 11/16 (68.8%) 24/38 (63.2%) 27/47 (57.4%)
Non-treatment 8/14 (57.1%) 101/24 (41.7%) 10/23 (43.5%)
P-value 0.538 0.003 0.001
Significant differences between metronidazole and paromomycin *(p = 0.007)
**(p = 0.011).
Table 6
Test results post treatment with metronidazole according to dose used.
Treatment Negative for D.
fragilis
P-value
Metronidazole Dose and duration
recommendeda
157/215 (73.0%)
Duration<10 days 71/110 (64.5%) p= 0.199
Underdosage 28/39 (71.8%) p= 0.97
Duration<10 days and
underdosage
36/79 (45.6%) p < 0,0001
a CDC recommendation.
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countries (Cacciò, 2018).
The pathogenic capacity of infection by D. fragilis and its clinical
manifestations vary widely, from asymptomatic cases or those with
mild symptoms to chronic symptoms (Damien Stark et al., 2016; Miguel
et al., 2018). Despite the considerable variability in symptomatology,
with mainly asymptomatic or mild clinical manifestations, its high
prevalence can generate a considerable disease load, leading to the use
of many healthcare resources. In this sense, to date, Dientamoebiasis has
been neglected (Garcia, 2016; Stark et al., 2016). In turn, the need to
establish specific healthcare policies to tackle this reality is increasingly
evident.
To the best of our knowledge, the sample in our study is one of the
largest used to evaluate subjects with D. fragilis and the therapeutic
response to different antiparasitic drugs. We show higher rates of era-
dication with paromomycin than with metronidazole. However, it is
still necessary to develop new studies that evaluate the clinical–par-
asitology correlation and the efficacy of the different therapeutic op-
tions for the treatment of infection by D. fragilis.
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